Pharming Group (NASDAQ:PHAR) Short Interest Down 68.4% in January

Pharming Group (NASDAQ:PHAR) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 7,500 shares, a decrease of 68.4% from the January 15th total of 23,700 shares. Based on an average trading volume of 7,200 shares, the days-to-cover ratio is presently 1.0 days.

Pharming Group Stock Up 3.5 %

Shares of Pharming Group stock traded up $0.30 during trading on Wednesday, reaching $8.86. The stock had a trading volume of 3,236 shares, compared to its average volume of 6,544. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $602.68 million, a price-to-earnings ratio of -34.07 and a beta of -0.10. The stock has a fifty day moving average price of $9.26 and a two-hundred day moving average price of $8.43. Pharming Group has a 52 week low of $6.65 and a 52 week high of $12.29.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PHAR. Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th. Finally, Oppenheimer reduced their price target on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, October 28th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.